¨Abstract
Background and Objectives: ... This study provides an in-depth account of various cardiovascular adverse events reported after the mRNA vaccines´ first or second dose including pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarction/STEMI, intracranial hemorrhage, thrombosis (deep vein thrombosis, cerebral venous thrombosis, arterial or venous thrombotic events, portal vein thrombosis, coronary thrombosis, microvascular small bowell thrombosis, and pulmonary embolism...
Results: A total of 81 articles analyzed confirmed cardiovascular complications post-COVID-19 mRNA vaccines in 17,636 individuals and reported 284 deaths ...
4. Discussion
... The effect of COVID‐19 mRNA vaccines is eminent from our results; however, identifying the number of dosages eliciting each stratified complication and time for symptom resolution for the respective occurrence is imperative for reviewing vaccine delivery plans. Due to the studies' variable reporting, this could not be distinguished in this review. Furthermore, more studies focusing on lab parameters and biomarkers are required to employ strategies to mitigate complications and observe disease courses. Only a small proportion of our selected publications mentioned these lab findings, which, considering the number of events reported, are insufficient to establish a criterion for detecting abnormalities. Prior research has revealed myocarditis to be more common in the younger population; it elucidates that dividing each condition based on age group can help discern predisposing factors and correlate vaccination and CV health. This key finding would allow strategizing vaccination in vulnerable population groups.
5. Conclusion
This systematic review provides essential data for immunization providers when evaluating the risk versus benefits of COVID‐19 mRNA vaccines on the CV system. CV events such as thrombosis, thrombocytopenia, stroke, and myocarditis frequently occur with the mRNA vaccines studied... Future studies must report adverse events by vaccine types and changes in lab parameters of relevant outcomes pre‐ and postvaccination.¨
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.